222 related articles for article (PubMed ID: 33858953)
1. Feasibility of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer during COVID-19 pandemic.
Ayhan A; Yilmaz Baran S; Vatansever D; Dogan Durdag G; Akilli H; Celik H; Taskiran C
Int J Gynecol Cancer; 2021 Jun; 31(6):883-887. PubMed ID: 33858953
[TBL] [Abstract][Full Text] [Related]
2. A Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Primary Advanced Ovarian Cancer: The First Reported Pilot Experience from Saudi Arabia.
Abu-Zaid A; Alomar O; Alsabban M; Salem H; Al-Badawi IA
Gulf J Oncolog; 2020 Sep; 1(34):19-25. PubMed ID: 33431358
[TBL] [Abstract][Full Text] [Related]
3. Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single-center, real-life experience.
Ghirardi V; Ronsini C; Trozzi R; Di Ilio C; Di Giorgio A; Cianci S; Draisci G; Scambia G; Fagotti A
Cancer; 2020 Dec; 126(24):5256-5262. PubMed ID: 32931024
[TBL] [Abstract][Full Text] [Related]
4. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.
Marrelli D; Petrioli R; Cassetti D; D'Ignazio A; Marsili S; Mazzei MA; Lazzi S; Roviello F
Surg Oncol; 2021 Jun; 37():101523. PubMed ID: 33545658
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced peritoneal surface tumors during the COVID-19 pandemic: A single-institution experience.
Radomski SN; Florissi I; Khan H; Siddiqi A; Paneitz DC; Johnston FM; Greer JB
J Surg Oncol; 2022 Dec; 126(8):1375-1382. PubMed ID: 36081374
[TBL] [Abstract][Full Text] [Related]
6. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
[TBL] [Abstract][Full Text] [Related]
7. Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
Gruner M; Chambers LM; Yao M; Chichura A; Morton M; Costales AB; Horowitz M; Rose PG; Debernardo R; Michener CM
Gynecol Oncol; 2021 Sep; 162(3):645-651. PubMed ID: 34247768
[TBL] [Abstract][Full Text] [Related]
8. Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery.
El Hajj H; Vanseymortier M; Hudry D; Bogart E; Abdeddaim C; Leblanc E; Le Deley MC; Narducci F
ESMO Open; 2021 Apr; 6(2):100098. PubMed ID: 33819750
[TBL] [Abstract][Full Text] [Related]
9. Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in elderly women with epithelial ovarian cancer: analysis of a prospective registry.
Chambers LM; Yao M; Morton M; Chichura A; Costales AB; Horowitz M; Gruner MF; Rose PG; Michener CM; DeBernardo R
Int J Gynecol Cancer; 2021 Jul; 31(7):1021-1030. PubMed ID: 34006567
[TBL] [Abstract][Full Text] [Related]
10. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
van Driel WJ; Koole SN; Sikorska K; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AGJ; Verwaal VJ; Kieffer JM; Van de Vijver KK; van Tinteren H; Aaronson NK; Sonke GS
N Engl J Med; 2018 Jan; 378(3):230-240. PubMed ID: 29342393
[TBL] [Abstract][Full Text] [Related]
12. A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer.
Yang D; Zhang Y; Gong P; Liu F; Gan Y; Bai W
J Obstet Gynaecol Res; 2023 Jul; 49(7):1795-1804. PubMed ID: 37231941
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
14. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S; van Stein R; Sikorska K; Barton D; Perrin L; Brennan D; Zivanovic O; Mosgaard BJ; Fagotti A; Colombo PE; Sonke G; Driel WJV;
Int J Gynecol Cancer; 2020 Jun; 30(6):888-892. PubMed ID: 32205449
[TBL] [Abstract][Full Text] [Related]
15. Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
Zivanovic O; Chi DS; Zhou Q; Iasonos A; Konner JA; Makker V; Grisham RN; Brown AK; Nerenstone S; Diaz JP; Schroeder ED; Langstraat CL; Paroder V; Lakhman Y; Soldan K; Su K; Gardner GJ; Andikyan V; Guo J; Jewell EL; Long Roche K; Troso-Sandoval T; Lichtman SM; Moukarzel LA; Dessources K; Abu-Rustum NR; Aghajanian C; Tew WP; Beumer J; Sonoda Y; O'Cearbhaill RE
J Clin Oncol; 2021 Aug; 39(23):2594-2604. PubMed ID: 34019431
[TBL] [Abstract][Full Text] [Related]
16. Initial experience of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a French hyperthermic intraperitoneal chemotherapy (HIPEC) expert center.
Ceribelli C; Debs T; Chevallier A; Piche MA; Bereder JM
Surg Endosc; 2020 Jun; 34(6):2803-2806. PubMed ID: 32166545
[TBL] [Abstract][Full Text] [Related]
17. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
[TBL] [Abstract][Full Text] [Related]
18. Misdiagnosis of appendiceal neoplasms as ovarian tumors: Impact of prior gynecologic surgery on definitive cytoreduction and HIPEC.
Garland-Kledzik M; Maithel S; Jafari MD; Dehkordi-Vakil F; Chaudhry H; Dinicu A; Chang I; Krasnoff C; Gambhir S; Sheehan B; Pigazzi A
Eur J Surg Oncol; 2022 Feb; 48(2):449-454. PubMed ID: 34454813
[TBL] [Abstract][Full Text] [Related]
19. Experience with the use of HIPEC in advanced serous ovarian cancer after complete and optimal cytoreduction.
Tsip NP; Kopetskiy VI; Polentsov YO; Yegorov MY; Vakulenko GO; Svintsitskiy VS
Exp Oncol; 2021 Mar; 43(1):67-72. PubMed ID: 33785709
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update.
Revaux A; Carbonnel M; Kanso F; Naoura I; Asmar J; Kadhel P; Ayoubi JM
Horm Mol Biol Clin Investig; 2020 Feb; 41(3):. PubMed ID: 32083444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]